Catalyst to Present Data on Clotting Factor Candidates at Hemophilia Congress

Margarida Azevedo, MSc avatar

by Margarida Azevedo, MSc |

Share this article:

Share article via email
Catalyst clotting factor candidates

Catalyst Biosciences will present three posters with data from its two investigational candidates for hemophilia at the upcoming 10th Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD) Feb. 1-3 in Paris, France.

The first poster presentation is for a next-generation factor VIIa, marzeptacog alfa (activated), that showed promise in a Phase 1 clinical trial in severe hemophilia A and B with and without inhibitors, according to a company press release.

Catalyst is also planning a study this year to evaluate the treatment in patients with hemophilia B with inhibitors.

The poster is titled “Pharmacokinetics And Pharmacodynamics Of Daily Subcutaneously Administered Marzeptacog Alfa (Activated) In Hemophilia Dogs, Levy et al.”

Marzeptacog alfa (activated), formerly known as CB 813d, was designed to allow for the effective, long-term prophylaxis in hemophilia patients with inhibitors.

The second and third poster presentations are about Catalyst’s CB 2679d/ISU304, a next-generation coagulation Factor IX variant. In preclinical studies, CB 2679d has shown significantly higher potency compared to other Factor IX (FIX) products on the market and in development.

In November 2016, the company reported positive preclinical data demonstrating that CB 2679d administrated subcutaneously (beneath the skin) in mice with hemophilia B resulted in a dose dependent increase in the Factor IX antigen, and also showed 17-times higher coagulation potency when compared to another FIX product (BeneFIX).

The company is planning to begin a proof-of-concept Phase 1/2 clinical trial evaluating CB 2679d in patients with hemophilia B later this year.

Here are the poster presentations for CB 2679d/ISU304 that will be presented at the EAHAD:

  • “Pharmacokinetics Of Subcutaneously Administered CB 2679d/ISU304 In Minipig Compared With Benefix, Hong et al.” (Poster P074).
  • “Pharmacokinetics And Pharmacodynamics Of Daily Subcutaneously Administered CB 2679d/ISU304 In Hemophilia B Dogs, Levy et al.” (Poster P075).

Catalyst is focused on the prevention of spontaneous bleeding in patients with hemophilia, even during surgery, using their coagulation factors. Currently available medicines are injected into a patient’s veins, but Catalyst believes a clotting factor that could instead be injected just under the skin would enhance the treatment of hemophilia patients.